Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polaprezinc plus esomeprazole for ulcers after endoscopic submucosal dissection
ChiCTR1900028329Phase 4Recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Dec 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Peptic ulcer disease (PUD) comparing Polaprezinc + esomeprazole with Esomeprazole (2 arms). Primary endpoint: Ulcer healing rate. Started Dec 2019; status: recruiting.
02
Drugs
polaprezincesomeprazole
03
Conditions
Peptic ulcer disease (PUD)
Beyond the preview
Go deeper on ChiCTR1900028329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028329.